Type I error inflation caused by batch-to-batch variability of Reference? [Design Issues]

posted by nobody – 2016-10-20 16:27 (3039 d 12:25 ago) – Posting: # 16746
Views: 8,715

❝ RLD batches not bioequivalent AND are NOT therapeutically equivalent => serious risk to public health. You kill the originator after establishing your product on the market :-D


...hmmm, would such a "Generic" get marketing authorization? Would you have to show "better" batch-to-batch performance for your generic formulation? I'm inclined to say: The originator has to get his quality issues under control (recall lousy batches from the market?) and no generic should be allowed AT ALL in the meantime.

This whole story reminds of the good old days when BE was invented to keep companies from marketing lousy products with erratic biopharmaceutical properties. Maybe it is time to get a little tougher on this inhalation-stuff?

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
76 visitors (0 registered, 76 guests [including 13 identified bots]).
Forum time: 03:53 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5